Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 + AK117 versus pembrolizumab for first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2400091840Phase 3Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab, ligufalimab and pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Union Hospital. Primary endpoint: overall survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400091840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091840.